Skip to main content
Caplight Logo









Embark Laboratories

Embark Laboratories

Private
CopenhagenHealthcare & Life Scienceshttps://embarklaboratories.com/

Last Round

M&A

Aug 30, 2023

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Embark Laboratories is a biotechnology company that focuses on the discovery and development of novel therapeutic targets for cardiometabolic diseases, including obesity and type 2 diabetes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug discoverycardiometabolic therapeuticstarget identificationbiotech R&DG protein-coupled receptorGPCRobesity researchdiabetes researchadipose tissue biologytherapeutic targetsdrug developmentpharma partnerbiotech spin-outdrug discovery platformobesity drug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Embark Laboratories Comparables

Compare Embark Laboratories with similar companies based on industry and business-model similarity.

Embark Laboratories comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Incipiam Pharma
79%
Antag Therapeutics
69%
Equator Therapeutics
69%

Embark Laboratories Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AAug 30, 2023

Key People

Founding team and executive leadership

Zach Gerhart-Hines

Chief Technology Officer

Executive Team

Embark Laboratories Investors

Notable investors and investment history

Embark Laboratories investors
InvestorRounds
Innovation Fund DenmarkSeed
Novo Nordisk FoundationSeed
Novo HoldingsSeed
European Research CouncilSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 661% MoM, from 66 to 502.

  • Apr 22, 2026

    Monthly visitors grew 155% MoM, reaching 1.1K.

Embark Laboratories Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Embark Laboratories Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Embark Laboratories's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range7
Year Founded2023
Last FundingAug 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?